340B Drug Pricing Program: What It Means for Patients

The 340B Drug Pricing Program is a federal initiative that requires pharmaceutical manufacturers to sell outpatient drugs at significantly reduced prices to eligible healthcare organizations. Established under Section 340B of the Public Health Service Act (42 U.S.C. § 256b), the program is administered by the Health Resources and Services Administration (HRSA). Understanding 340B is directly relevant to patients who receive care at safety-net facilities, as it affects drug pricing, cost-sharing obligations, and the range of services these facilities can offer.

Definition and scope

The 340B program was enacted as part of the Veterans Health Care Act of 1992 (Public Law 102-585) and took effect in 1993. It operates as a ceiling price mechanism: covered entities purchase outpatient drugs at or below a federally mandated ceiling price, which HRSA calculates quarterly based on the Average Manufacturer Price minus a statutory rebate percentage defined in statute.

Eligible covered entities fall into two broad categories under HRSA classification:

Category 1 — Disproportionate Share Hospitals (DSH): Hospitals that meet a DSH adjustment threshold under Medicare, children's hospitals, critical access hospitals, free-standing cancer hospitals, rural referral centers, and sole community hospitals.

Category 2 — Non-Hospital Covered Entities: Includes Federally Qualified Health Centers (FQHCs), FQHC Look-Alikes, Ryan White HIV/AIDS Program grantees, Title X family planning clinics, hemophilia treatment centers, black lung clinics, urban Indian organizations, and tribal/urban Indian health programs under the Indian Health Service. Effective January 5, 2021, urban Indian organizations and their employees are deemed to be part of the Public Health Service for purposes of certain personal injury claims under enacted federal legislation, meaning that malpractice and personal injury liability for these entities and their staff is governed by the Federal Tort Claims Act rather than standard civil litigation frameworks.

As of the HRSA Office of Pharmacy Affairs' published program data, more than 50,000 sites were registered in the 340B program across all entity types. Manufacturers participating in Medicaid are legally required to participate in 340B — non-participation results in loss of Medicaid and Medicare Part B reimbursement eligibility.

Patients who receive care at a covered entity do not enroll in 340B individually. The program operates at the institutional level, and its patient-facing impact is structural rather than application-based.

How it works

The operational mechanics of 340B involve a defined sequence of requirements that covered entities must satisfy before and during program participation.

  1. Registration: Covered entities register with HRSA through the Office of Pharmacy Affairs Information System (OPAIS). Registration requires documentation of eligible status and is subject to annual recertification.
  2. Ceiling price calculation: HRSA publishes the 340B ceiling price for each covered drug. The ceiling equals the Average Manufacturer Price (AMP) minus the unit rebate amount — the same rebate formula used in the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8).
  3. Drug dispensing models: Covered entities may dispense 340B drugs through an in-house pharmacy or through a contracted external pharmacy. Contract pharmacies are permitted under a 1996 HRSA policy that was significantly expanded in a 2010 guidance notice; their use has been a source of ongoing manufacturer litigation as of 2023.
  4. Patient eligibility definition: HRSA's "patient definition" guidance specifies that an individual qualifies as a patient of a covered entity only if the entity has an established relationship with that individual and maintains records of care. A patient who receives only a prescription from a covered entity's pharmacy — without a clinical relationship — does not meet the program's patient definition.
  5. Duplicate discount prohibition: Federal law prohibits covered entities from receiving both a 340B discount and a Medicaid rebate on the same drug unit. Entities must track this using carve-in or carve-out approaches to Medicaid billing.
  6. Audit and oversight: HRSA conducts audits of covered entities and manufacturers. Manufacturers found to overcharge covered entities may face civil monetary penalties under 42 U.S.C. § 256b(d)(1)(B)(vi).

Understanding prescription drug assistance programs in the broader context clarifies where 340B sits relative to manufacturer patient assistance programs, state pharmaceutical assistance programs, and Medicaid — each of which operates under distinct eligibility criteria.

Common scenarios

Scenario A — Uninsured patient at a community health center: A patient without insurance receives care at a registered FQHC. The FQHC purchases the prescribed medication at the 340B ceiling price and may pass some or all of that discount to the patient at the point of dispensing. The extent of cost reduction to the patient depends on the FQHC's internal policy — the program does not mandate patient-level price pass-through.

Scenario B — Insured patient with a contract pharmacy arrangement: A covered entity holds a contract pharmacy agreement with a retail chain. The patient's prescription is filled at that retail location using 340B-purchased drug inventory. The patient's cost-sharing is typically determined by their insurance plan, not by the 340B acquisition cost. Patients with health insurance coverage may see no direct out-of-pocket difference despite the entity's reduced acquisition cost.

Scenario C — Medicaid beneficiary and duplicate discount risk: A Medicaid-enrolled patient receives a drug at a covered entity. If the entity bills Medicaid for the drug and also received the 340B discount, a duplicate discount violation occurs. Entities using "carve-out" exclude Medicaid claims from 340B inventory; those using "carve-in" do not dispense 340B drugs to Medicaid patients.

Scenario D — Hospital outpatient department (HOPD): A qualifying DSH hospital registers its outpatient clinic as a 340B site. Patients receiving chemotherapy or specialty drugs in this setting may benefit from the hospital's 340B savings, though — as in Scenario B — the financial benefit may accrue to the institution rather than reducing the patient's cost-sharing.

Scenario E — Urban Indian organization: Effective January 5, 2021, urban Indian organizations and their employees are deemed part of the Public Health Service for purposes of certain personal injury claims, pursuant to enacted federal legislation. Patients receiving care at an urban Indian organization that participates in 340B should be aware that this deemed status affects the legal framework governing malpractice and personal injury liability for those providers, with claims processed under the Federal Tort Claims Act rather than through standard civil litigation.

For patients navigating financial hardship independent of 340B, patient financial assistance programs and charity care eligibility provide supplementary frameworks.

Decision boundaries

340B operates within defined legal and regulatory limits. The following boundaries determine program applicability.

What 340B covers:
- Outpatient drugs only. Inpatient drugs dispensed to admitted hospital patients are excluded from 340B pricing.
- Drugs purchased for patients who meet HRSA's established patient definition.
- Drugs listed in covered outpatient drug categories as defined under the Medicaid Drug Rebate Program.

What 340B does not cover:
- Inpatient drug costs. A patient admitted to a 340B-registered hospital does not receive 340B pricing on drugs administered during inpatient stays.
- Guaranteed patient-level discounts. The program reduces acquisition cost for covered entities but does not legally require entities to reduce patient charges by a corresponding amount.
- All pharmaceutical products. Orphan drugs are subject to use restrictions for certain covered entity types, an area of ongoing regulatory dispute between manufacturers and HRSA.

Manufacturer restrictions (post-2020 disputes): Beginning in 2020, a group of pharmaceutical manufacturers began restricting 340B drug pricing for certain contract pharmacy arrangements. HRSA issued advisory opinions asserting these restrictions violated the statute. Federal court decisions through 2023 produced a split in circuit interpretations, with the Third Circuit and D.C. Circuit reaching different conclusions on manufacturer obligations. HRSA's enforcement authority in this domain remained contested as of those rulings.

Urban Indian organization liability framework (effective January 5, 2021): Pursuant to enacted federal legislation effective January 5, 2021, urban Indian organizations and their employees are deemed to be part of the Public Health Service for purposes of certain personal injury claims. This means that personal injury and malpractice claims against these entities and their staff are governed by the Federal Tort Claims Act, altering the legal process available to patients who believe they have been harmed while receiving care at such organizations.

Comparison — 340B vs. Medicaid Drug Rebate Program (MDRP): Both programs reduce manufacturer revenue on covered drugs, but they operate through different mechanisms. The MDRP provides retrospective rebates paid to state Medicaid agencies after dispensing; 340B provides prospective ceiling prices at the point of purchase. A single drug unit cannot receive both benefits simultaneously — the prohibition at 42 U.S.C. § 256b(a)(5)(A) is absolute.

Patients seeking to understand their full range of cost-reduction options alongside 340B should also review the structure of copay, deductible, and out-of-pocket maximum obligations, which determine actual patient expenditure independent of how a covered entity acquires its drug supply.

References

📜 8 regulatory citations referenced  ·  ✅ Citations verified Feb 25, 2026  ·  View update log

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Bmi Health Metrics Calculator